Odeon Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

OBI Pharma Inc (浩鼎生技) has signed an agreement with Odeon Therapeutics (Hong Kong) Ltd (康騰浩諾香港生物科技) to give it the rights to two of its experimental drugs, OBI-833 and OBI-999, in China, OBI said on Tuesday. OBI would receive US$200 million for the licensing of the cancer drugs, which includes US$12 million in newly issued Odeon shares as a signing payment, and US$188 million as development and commercialization milestone payments, the Taipei-based company said in a regulatory filing. The drug developer would also receive double-digit percentage royalties on Odeon’...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

OBI is eligible to receive up to US$ 200 million in total milestone payments and tiered double-digit royalties on net sales. TAIPEI, Taiwan, Feb. 22, 2022 /PRNewswire/ -- OBI Pharma, Inc.

/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...

/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...